PUBLISHER: The Business Research Company | PRODUCT CODE: 1705229
PUBLISHER: The Business Research Company | PRODUCT CODE: 1705229
Keytruda, also known as pembrolizumab, is a monoclonal antibody medication utilized in cancer treatment. It falls under the category of immune checkpoint inhibitors, working by targeting and blocking the PD-1 (programmed cell death protein 1) protein in immune cells. This action assists the immune system in recognizing and attacking cancer cells effectively.
Keytruda is primarily used in treating various cancer types, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. Melanoma, specifically, is a type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment giving skin its color. The medication is available through different payer types such as commercial, Medicare, and Medicaid, and distributed through various channels such as hospital pharmacies and specialty pharmacies.
The keytruda market research report is one of a series of new reports from The Business Research Company that provides keytruda market statistics, including keytruda industry global market size, regional shares, competitors with a keytruda market share, detailed keytruda market segments, market trends and opportunities, and any further data you may need to thrive in the keytruda industry. This keytruda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The keytruda market size has grown rapidly in recent years. It will grow from $21.6 billion in 2024 to $23.8 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to improved patient outcomes, increased adoption of immunotherapy, research and development, improved patient compliance, and increased adoption of keytruda.
The keytruda market size is expected to see strong growth in the next few years. It will grow to $34.61 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding indications, emerging markets, increasing prevalence of cancer, rising healthcare expenditure, and growing demand for precision medicine. Major trends in the forecast period include demand for targeted therapies, advances in immunotherapy, advances in diagnostic technologies, demand for cancer treatment, and advances in cancer research.
The rising prevalence of cancer is expected to drive the growth of the Keytruda market in the coming years. Cancer is a complex set of diseases marked by the abnormal growth and spread of cells. Various factors, including genetics, lifestyle, environment, and hormones, contribute to the rising incidence of cancer. Keytruda (pembrolizumab) aids in cancer treatment by utilizing the body's immune system to more effectively combat cancer cells. It represents a major breakthrough in cancer therapy by empowering the immune system to target and destroy cancer cells, offering new hope for patients with advanced or metastatic cancers. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that cancer cases had increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth rate of 2.19%. Therefore, the growing prevalence of cancer is driving the expansion of the Keytruda market.
Leading companies in the Keytruda market are focused on developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab, a monoclonal antibody medication belonging to immune checkpoint inhibitors, is marketed under the brand name Keytruda. It targets and inhibits a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells. For instance, in November 2023, Merck, a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy approved by the Food and Drug Administration (FDA). This combination therapy has shown significant improvements in overall survival and progression-free survival compared to chemotherapy alone, presenting a promising advancement in gastric cancer treatment. Clinical trials have demonstrated enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to standalone chemotherapy.
In May 2024, CytomX Therapeutics, a US-based biotechnology company, partnered with Merck to assess CX-801 with KEYTRUDA (pembrolizumab) in patients with advanced metastatic solid tumors. This collaboration aims to evaluate the safety, tolerability, and preliminary efficacy of CX-801 in combination with KEYTRUDA for advanced metastatic solid tumors. Merck, a US-based company, offers Keytruda as part of its pharmaceutical portfolio.
Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.
North America was the largest region in the keytruda market in 2024. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the keytruda market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The keytruda market consists of sales of immunotherapy, combination therapies, clinical trials, and personalized medicine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Keytruda Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on keytruda market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for keytruda ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The keytruda market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.